BCL2 and glioblastoma: Furthermore, TP53wt GSCs are resistant against mTORC1/2 inhibitors via Bcl-2; combined blockade of mTORC1/2 and Bcl-2 is worth exploring further in TP53wt glioblastomas, or in TP53mut tumors to prevent the outgrowth of resistant subclones during mTORC1/2 inhibition.